Dabrafenib is an inhibitor of mutated BRAF kinase and has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma. Molecular Formula: C23H20F3N5O2S2 Solubility: Chloro
Molekulargewicht:
519.56
Formulierung:
Supplied as a white to off-white solid.
CAS Nummer:
[1195765-45-7]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten